Intellia presents positive data for hereditary angioedema treatment
LONDON - EKF Diagnostics Holdings plc (AIM:EKF), a global diagnostics business, announced Monday it has purchased 929,169 of its ordinary shares at a weighted average price of 27.5269 pence per share. The shares will be held in treasury, according to a company statement.
The share buyback was executed on October 17, with purchases made in three separate transactions on the AIM exchange. The company paid prices ranging from 27.5 pence to 28 pence per share.
Following the buyback, EKF’s total issued share capital consists of 449,093,790 ordinary shares, with 2,655,714 shares held in treasury. The total number of ordinary shares carrying voting rights is now 446,438,076.
As part of the transaction, EKF acquired 274,000 ordinary shares at 28 pence per share from Harwood, acting as investment manager to Oryx International Growth Fund Limited and North Atlantic Smaller Companies Investment Trust PLC. The company purchased 91,333 shares from Oryx and 182,667 shares from NASCIT.
The company noted that Harwood facilitated this transaction to ensure that the aggregate indirect beneficial interest of Christopher Mills, a Non-Executive Director, remains at approximately the same level and does not exceed 30% of the total voting rights following the repurchases. Mills’ aggregate indirect interest in the company now stands at 131,650,000 ordinary shares.
EKF Diagnostics operates five manufacturing sites across the US and Germany, selling into over 120 countries worldwide. The company specializes in point-of-care analyzers in hematology and diabetes, as well as life sciences services providing enzymes and custom products for diagnostic, food, and industrial applications.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.